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Background: Multiple sclerosis (MS) is an autoimmune disease in which dysregulated immune cells attack myelin
in the central nervous system (CNS), leading to irreversible neuronal degeneration. Our previous studies have
demonstrated that epidermal fatty acid binding protein (E-FABP), widely expressed in immune cells, in particular in
dendritic cells (DCs) and T lymphocytes, fuels the overactive immune responses in the mouse model of
experimental autoimmune encephalomyelitis (EAE).
Methods: In the present study, we conducted an intensive computational docking analysis to identify novel E-FABP
inhibitors for regulation of immune cell functions and for treatment of EAE.
Results: We demonstrate that compound [2-(4-acetylphenoxy)-9,10-dimethoxy-6,7-dihydropyrimido[6,1-a]isoquinolin-4-
one; designated as EI-03] bound to the lipid binding pocket of E-FABP and enhanced the expression of peroxisome
proliferator-activating receptor (PPAR) γ. Further in vitro experiments showed that EI-03 regulated DC functions by
inhibition of TNFα production while promoting IL-10 secretion. Moreover, EI-03 treatment counterregulated T cell
balance by decreasing effector T cell differentiation (e.g. Th17, Th1) while increasing regulatory T cell development.
Most importantly, mice treated with this newly identified compound exhibited reduced clinical symptoms of EAE
in mouse models.
Conclusions: Taken together, we have identified a new compound which displays a potential therapeutic benefit
for treatment of MS by targeting E-FABP.
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Multiple sclerosis (MS) continues to be a serious public
health problem without a curative treatment. Although
the development of MS is attributed to a combination of
genetic and environmental factors, the exact cause of
MS is not completely understood [1,2]. The goals of MS
therapy are to modify the disease course and to manage
relapses and symptoms. For example, finglolimod has
been shown to reduce relapses of MS patients by pre-
venting pathogenic lymphocyte infiltration into the cen-
tral nervous systems (CNS) [3,4]. However, a substantial
proportion of MS patients do not respond well to the* Correspondence: bli@hi.umn.edu
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unless otherwise stated.currently available medications. Therefore, identification
of new targets for management of MS is urgently
needed.
Fatty acid binding proteins (FABPs) constitute a family
of cytosolic proteins which exhibit distinct tissue specifi-
city [5]. As lipid chaperones, FABPs can regulate cellular
metabolism and function through enabling fatty acid dis-
tribution and coordinating their responses. Since fatty
acids function both as energy sources and as signaling
molecules, FABPs have been identified as central regula-
tors of metabolic and inflammatory pathways [6-9]
Using a mouse model of MS, experimental autoimmune
encephalomyelitis (EAE), we have demonstrated that
mice deficient of FABPs, in particular epidermal FABP
(E-FABP), have protection from the development of EAE
[10,11]. E-FABP deficient dendritic cells (DCs) areis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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promoting Th1 and Th17 responses [11]. Furthermore,
we have shown that CD4+ T cells deficient for E-FABP
exhibit increased expression of peroxisome proliferator-
activating receptor γ (PPARγ), which suppressed Th17
differentiation while enhancing regulatory T cell (Treg)
development [10]. Based on our previous studies, it has
become clear that the protection against EAE exhibited
by E-FABP-deficient mice is due to the E-FABP-deficient
phenotype of the antigen presenting cells (APCs) as well
as of the T cells, themselves. Thus, E-FABP represents a
new therapeutic target for EAE treatment, and modulat-
ing E-FABP activity may provide an attractive strategy
for MS management.
Recently, many studies have reported the development
of specific inhibitors which can modify FABP functions
[12-15]. For example, BMS309403, a small molecule in-
hibitor of adipose FABP (A-FABP), has been shown to
treat atherosclerosis and type 2 diabetes in mouse
models [16], suggesting that inhibition of FABP activity
is an effective approach for treatment of inflammatory
diseases and metabolic syndromes. Herein, we identi-
fied 2-(4-acetylphenoxy)-9,10-dimethoxy-6,7-dihydro-
pyrimido[6,1-a]isoquinolin-4-one (i.e., EI-03) as a novel
E-FABP inhibitor using a ligand docking computational
method [17,18]. Experimental evidence further con-
firmed that EI-03 effectively inhibited E-FABP activity
in both DCs and T cells and potently reduced EAE
symptoms in mouse models.
Methods
Computational modeling for E-FABP inhibitors
The three-dimensional structure of E-FABP was obtained
from Protein Data Bank (PDB ID 1B56). The crystal struc-
ture was processed using the Protein Preparation Wizard
in Maestro v9.3. Hydrogens were added consistent with a
pH of 7.0. All water molecules were removed. Then the
structure was energy minimized with an RMSD cutoff of
0.3 Å. The receptor grid was created with the centroid of
the crystal ligand as the center. Virtual screening was car-
ried out using the program Glide v5.7 [19]. Flexible dock-
ing was performed with the standard precision (SP) mode.
More than one million commercially available compounds
were downloaded from ZINC database and screened for
potential inhibitors of E-FABP. The top-ranked com-
pounds were clustered into different classes based on
similarity of chemical structures. Finally, 5 commercially
available compounds with distinct structures were pur-
chased from Interbio Screen Ltd for following experimen-
tal tests.
E-FABP purification and thermal shift assays
Recombinant His6-tagged E-FABP was over-expressed
and purified from BL21 (DE3) cells. Protein was purifiedby Ni-NTA resin. Additional purification steps included
cleavage of His6-tag using TEV protease followed by
ion-exchange chromatography. Complete removal of en-
dogenous lipids was ensured by final purification on
Lipidex-1000 column. Purified apo E-FABP protein was
used to probe small molecule compounds in a fluores-
cence based thermal shift assay [20]. Reactions were set-
up in PCR tubes in a 20 μl volume containing 10 μM E-
FABP and 10× SYPRO Orange dye (Invitrogen) in
20 mM HEPES pH 7 and 150 mM NaCl, containing ei-
ther test compounds or DMSO only controls. Tested
compounds were added at increasing concentrations
such that the DMSO concentration never exceeded 2%.
PCR tubes were then sealed, centrifuged and heated
from 25 to 95 degrees at a rate of 1 degree/min on 7500
Real-Time PCR machine (Applied Biosystems). Raw data
analysis and curve fitting to calculate Tm values was per-
formed as previously described [20].
Generation of bone marrow-derived dendritic cells
(BMDCs)
Femurs and tibias from 8- to 10-wk-old mice were
flushed with PBS, supplemented with 2% FBS to collect
the bone marrow. Red cells in the bone marrow were
lysed with red cell lysis buffer (R&D systems). The bone
marrow was washed in DPBS and plated in 100-mm tis-
sue culture dishes with 5% FBS RPMI 1640 medium at
37°C/5% CO2 for 4 hours. Then the non-adherent cells
were plated in 5% FBS RPMI 1640 medium with 20 ng/
ml GM-CSF (R&D Systems). New 5% FBS RPMI 1640
medium with 20 ng/ml GM-CSF was added on day 2
and day 5. The cultured BMDCs were collected on day 7
for further experiments.
Real-time PCR
For real-time PCR analyses, RNA was extracted from
cells using RNeasy Mini Kit (Qiagen). cDNA synthesis
was performed with QuantiTect Reverse Transcription
Kit (Qiagen). Quantitative PCR was performed with
SYBR® Green PCR Master Mix using ABI 7500 Real-
Time PCR Systems (Applied Biosystems). PPARβ/δ,
PPARγ, TNFα, IL-10 and β-actin expression was ana-
lyzed by QuantiTect primer assays (Qiagen). Results
were normalized to β-actin. Relative expression of the
target genes was measured using the ΔΔCT approach.
Confocal analysis
BMDCs cultured on poly-D-lysine coated coverslips
(NeuVitro) in a 24-well plate were treated with EI-03
(10 μM) or DMSO control for 18 hours. After fixation
and permeabilization, the cells were stained with anti-
PPARγ antibody (EMD Millipore). Nuclei of BMDCs
were stained with DAPI. Confocal analysis was per-
formed with Nikon Eclipse TE2000 confocal microscopy.
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1 × 106 BMDCs were stimulated with Mtb (50 μg/ml) for
6 hours in the presence or absence of indicated concen-
trations of EI-03. Culture supernatants were collected
for measurement of protein levels of TNFα and IL-10
with mouse ELISA kits (Biolegend) according to manu-
facturer’s instructions.
T cell culture in vitro
Mouse naïve CD4+ T cells or CD8+ T cells were sepa-
rated with a BD FACS Aria II Cell Sorter. Naïve CD4+
or CD8+ T cells were cultured with stimulation of anti-
CD3 (5 μg/ml) and anti-CD28 (2 μg/ml). Th1 or CTL
cells were differentiated with IL-12 (10 ng/ml); Th17
were induced with IL-6 (20 ng/ml) and TGFβ (1 ng/ml);
Tregs were induced with TGFβ (1 ng/ml). In some ex-
periments, cells isolated from spleen or lymph nodes
were stimulated with anti-CD3/CD28 in the presence or
absence of EI-03 (10 μM) for measurement of IFNγ pro-
duction or Foxp3 expression in CD4+ T cells.
Flow cytometric and cell sorting
Immune cells from draining lymph nodes or spleens
were subjected to surface staining or cultured with PMA
(5 ng/ml; Sigma), ionomycin (500 ng/ml; Sigma) and
Golgiplug (BD) for 6 hours, then harvested for surface
and intracellular staining. Flow cytometric data were col-
lected with a BD FACS Calibur™. Flow cytometric data
analyses were performed with Flowjo (Tree Star). The
following antibodies were used for cell staining: anti-
CD4 (clone RM4-5), anti-CD8 (clone 53–6.7), anti-MHC
class II (clone M5/114.15.2), anti-IFN-g (clone XMG1.2),
anti-IL-17 (clone TC11-18H10.1), anti-Foxp3 (clone FJK-
16 s), anti-CD80 (clone 16-10A1) and anti-CD86 (clone
GL-1).
Mice and the EAE model
C57BL/6 mice were bred and maintained in the animal
facility in the Hormel Institute in accordance with the
University of Minnesota Institutional Animal Care and
Use Committee (IACUC). Six to ten-week-old female
mice were utilized for experiments. All animal protocols
were approved by IACUC in the University of Minne-
sota and followed national guidelines. EAE was induced
as previously described [10]. Briefly, Mice were injected
in the flank with a 100 μl of emulsion containing 100 μg
of MOG35–55 in CFA (Sigma-Aldrich) supplemented
with 500 ng of Mycobacterium tuberculosis (Mtb) H37Ra
(Difco Laboratories). Mice were injected i.p. with 200 ng
of pertussis toxin (List Biological Laboratories) immedi-
ately following MOG35–55 injection (day 0) and again
2 days post immunization. For treatment with EI-03, EI-
03 (10 mg/kg or 20 mg/kg) in 200 μl PBS was injected
into mice by i.p. from day 0 or day 8 and injected everytwo days till day 20, the same volume of DMSO in PBS
was injected into mice by i.p. as control. Clinical scores
were designated numerically according to the following:
0, no detectable EAE symptoms; 1, tail paralysis/loss of
tonicity; 2, abnormal gait; 3, hind limb paralysis; 4, hind
limb and forelimb paralysis; and 5, moribund or dead;
0.5 gradations were assigned for intermediate scores.
Isolation of mononuclear cells from mouse CNS
Brain and spinal cord of EAE mice were removed and
cut into small pieces in a 70 mm cell strainer placed in a
10 cm petri dish containing 10 ml of ice-cold PBS. Each
piece of the organ was pressed through the cell strainer
using the back of a sterile 1 ml syringe plunger. After
several washes of the cell-strainer, all collected cell sus-
pensions were combined and centrifuged for 10 min at
400 g. The cells were resuspended with 7 ml PBS + 30%
Percoll and overlay onto 3 ml of PBS + 70% Percoll and
centrifuged at 800 g for 20 min at room temperature.
The fat on the top of the tube was removed and the cells
from the interface were collected and washed twice with
PBS.
Statistical analysis
All quantitative data were shown as means ± SD. Un-
paired, two-tailed Student’s t-test was performed for
comparison of results from different treatments. P value
less than 0.05 is considered statistically significant.
Results
In-silico screening of potential E-FABP inhibitors
To identify novel E-FABP inhibitors, an intensive
computer-aided molecular docking analysis using Glide
v5.7 [19] was performed to screen 1 million drug-like
compounds in chemical and natural compound libraries
based on the crystal structure of E-FABP. First, an initial
rough positioning and scoring phase was followed by
torsionally flexible energy optimization on an OPLS-AA
non-bonded potential grid for a few hundred surviving
candidate poses. Next, the selected candidates with glide
score less than −5.0 were refined via a Monte Carlo
sampling of pose conformation and further evaluated
using Glide XP (XP) mode for glide score and glide en-
ergy. Finally, the very best candidates were clustered
using Canvas and top 10 representative compounds with
diverse chemical structures were identified as the most
promising E-FABP inhibitors (EI). As listed in Table 1, 5
commercially available compounds were purchased and
tested experimentally for functional analyses using both
in vitro and in vivo assays.
Molecular docking model of E-FABP/Inhibitor interactions
In our previous studies, we demonstrated that E-FABP
deficient T cells exhibit elevated expression of PPARγ,
Table 1 In-silico screening of potencial E-FABP inhibitors
No. Molecular formula Molecular weight IUPAC name
EI-01 C22H29N3O7 447.48816 benzyl 2-(((R-methoxy-2-oxoethyl)amino)-4-methyl-1-oxopentan-2-yl)carbamoyl)-
5-oxopyrrolidine-1-carboxylate
EI-02 C20H18N4O4 378.38732 1-phenyl-6-(3,4,5-trimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one
EI-03 C22H20N2O5 392.4112 2-(4-acetylphenoxy)-9,10-dimethoxy-6,7-dihydro[6,1-a]isoquinolin-4-one
EI-04 C20H14N4O 326.35736 2-(furan-2-yl)-1-(m-tolyl)-1H-imi-dazo[4,5-b]quinoxaline
EI-06 C20H19NO5 353.37456 2-((−hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)-N-propylacetamide
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sion [10]. Thus, we tested all the potential E-FABP in-
hibitors by measuring alterations of PPAR expression in
T cells. While all the tested inhibitors displayed minimal
impact on PARβ/δ expression (Figure 1A), EI-03 re-
markably enhanced PPARγ expression in CD4+ T cells
and BMDCs (Figure 1B, C). These data suggested that
EI-03 (see detailed structure in Figure 1C) is able to
functionally inhibit E-FABP activity. We next analyzed
the binding characteristics of EI-03 with E-FABP ob-
tained from the molecular docking studies (Figure 1D).
In this model, the binding pocket of E-FABP remained
virtually unaltered and the EI-03 adopted the U-shaped
conformation similar to what has been observed in the
previous complex structures with fatty acid ligands (PDB
access code 4LKT). The main E-FABP/EI-03 interac-
tions consisted of five hydrogen bonds with the side
chains of Tyr22, Arg81, and Try131 and backbone
carbonyl oxygen of Met35 as well as van der Waals
interactions with the surrounding hydrophobic resi-
dues. Tyr131 made a bidentate hydrogen bonding in-
teractions with O4 and O5 of the inhibitor, maintaining
the same interaction with the polar head group of the
natural fatty acid ligands. Altogether, our data indicate
that EI-03 displayed an optimal fitting with favorable
interactions around the lipid binding pocket of
E-FABP.
EI-03 binds directly to E-FABP
On the basis of tight interactions of the EI-03/E-FABP
complex indicated by the molecular docking model, we
next performed an in vitro binding assay with the
recombinant protein to confirm the direct binding of EI-
03 to E-FABP. To obtain pure apo-proteins, residual
endogenous ligands of E-FABP were removed by lipidex-
chromatography (Figure 2A). The direct binding of EI-
03 to E-FABP was measured by the thermal shift assay
[20]. In this assay, the thermal stability of E-FABP was
monitored by measuring the fluorescent signal of Sypro
Orange in the presence or absence of the potential li-
gands. As shown in Figure 2B, EI-03 binding to E-FABP
increased the temperature of unfolding of E-FABP (Tm)
in a dose-dependent manner. In contrast, there was nochange of Tm in the presence of compound EI-06 under
the same conditions, suggesting a specific binding of EI-
03 to E-FABP. Consistent with the molecular modeling
results, these data further indicate that EI-03 specifically
binds to E-FABP and thus inhibits its lipid-binding
activity.
EI-03 regulates cytokine production by DCs
We have shown that E-FABP-deficient DCs exhibited re-
duced production of proinflammatory cytokines, but in-
creased production of anti-inflammatory cytokines [11].
To this end, we examined whether DCs with inhibition of
E-FABP activity by EI-03 mimicked the phenotype of E-
FABP-deficient DCs. First, we determined the effects of EI-
03 on cytokine production by DCs stimulated with Mtb,
the most common adjuvant used in EAE models. EI-03
treatment significantly suppressed TNFα and IL-6 produc-
tion by DCs at the transcriptional levels (Figure 3A, B). In
contrast, mRNA levels of IL-10, but not IL-1β, by DCs was
greatly elevated in the presence of EI-03 (Figure 3C, D).
When we collected the cultural supernatants and measured
each cytokine by ELISA, we confirmed above effects of EI-
03 treatment of DCs at the protein levels (Figure 3E-H).
We next analyzed the effects of EI-03 on expression
of surface molecules which were critical for Ag pres-
entation on DCs. As shown in Figure 3I-K, in re-
sponse to Mtb stimulation, CD80, CD86, and MHC
class II molecules were greatly upregulated. However,
EI-03 treatment had no impact on the expression of
MHC class II, CD80 and CD86 on Mtb-stimulated
DCs, suggesting a minimal effect of EI-03 on antigen
presentation. Therefore, EI-03 may regulate the function
of antigen present cells by controlling the balance of cyto-
kine production.
EI-03 inhibits the differentiation of effector T cells
As E-FABP expression in T cells promotes Th17 differ-
entiation [10], we reasoned that inhibition of E-FABP
with EI-03 suppressed the production of IL-17 by CD4+
T cells. To this end, we differentiated naïve CD4+ T cells
into Th17 cells with TGF-β/IL-6 in the presence or ab-
sence of EI-03. Indeed, EI-03 treatment significantly
inhibited Th17 differentiation in vitro (Figure 4A). Of
Figure 1 (See legend on next page.)
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Figure 1 Screening of E-FABP inhibitors. T cells were isolated and incubated with potential E-FABP inhibitors (10 μM) or DMSO control for
overnight. Expression of PPARβ/δ (A) and PPARγ (B) was examined by realtime-PCR (*, p < 0.05 as compared to the DMSO control). (C) Confocal
analysis of PPARγ protein expression in BMDCs cultured either with DMSO or with EI-03 (10 μM) for 18 hours (green: PPARγ, blue: nuclei).
(D) Chemical structure of the EI-03 (2-(4-acetylphenoxy)-9,10-dimethoxy-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one). (E) Analysis of EI-03/E-FABP
complex by a computational model. The protein was shown as a ribbon diagram and a partially transparent surface representation while the
docked compound is shown as a ball-and-stick model. The inset shows a zoomed-in view of the main interactions highlighted by a network of
hydrogen bonds.
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in vitro, IFNγ production in Th1 cells was significantly
reduced (Figure 4B). To further confirm this observa-
tion, we directly cultured lymphocytes from lymph
nodes (LNs) with anti-CD3/CD28 antibodies in the pres-
ence of EI-03, and showed that IFNγ production from
CD4+ T cells was also significantly inhibited by EI-03
treatment (Figure 4C). In contrast, Foxp3+ Tregs were
upregulated with treatment of EI-03 (Figure 4D), which
was consistent with what we observed in our previous
studies [10]. Interestingly, CD8+ T cells from LNs also
exhibited impaired IFNγ production in response to EI-
03 treatment (Figure 4E). Moreover, cells isolated from
spleen showed similar phenotypes in the presence of EI-
03 (data not shown). Thus, our data demonstrated that
EI-03 treatment counter-regulates the balance of ef-
fector T cells and Tregs in vitro. Due to the pathogenic
roles of Th1 and Th17 cells and protective roles of
Tregs in EAE development [21,22], these results imply
that EI-03 could potentially inhibit EAE development
through suppressing effector T cells and promoting
Tregs, thereby representing a good drug candidate for
EAE treatment.
EI-03 treatment ameliorates EAE symptoms in vivo
Given the evidence that EI-03 regulated the functions of
both APCs and T cells, suggesting a favorable outcome
for treatment of autoimmune diseases, we evaluated theFigure 2 EI-03 binds directly to E-FABP. (A) A coomasie-stained gel depict
thermal shift assays. (B) Normalized melting curves depicting enhanced the
shift of 1.0-2.1°C when compared to EI-06 or DMSO control. The data showtherapeutic efficacy of EI-03 using EAE models in vivo.
We treated mice with EI-03 concurrent with MOG
immunization on day 0 of the EAE model. We found that
EI-03 treatment significantly ameliorated the severity of
EAE disease with reduced clinical scores (Figure 5A). Fur-
ther analyses showed that mice treated with EI-03 exhib-
ited reduced numbers of total infiltrated leukocytes, into
the CNS as compared to mice treated with vehicle control
(Figure 5B). More specifically, the percentage of CD4+ T
cells, CD8+ T cells and CD11b+MHCII+ populations in EI-
03 treated mice was significantly lower than those in con-
trol mice (Figure 5C-E). Consistent with the in vitro data,
CD4+ T cells in the CNS of EI-03-treated mice exhibited
reduced production of IL-17 and IFNγ, but elevated ex-
pression of Foxp3, when compared to those from control
mice (Figure 5F, G). In addition, CD8+ T cells in the CNS
also displayed reduced expression of IFNγ in EI-03 treated
mice (Figure 5H).
Notably, when we treated mice with different dosages
of EI-03, we found that there was no additional benefit
at a higher dosage (20 mg/kg) of EI-03 (Figure 6A), sug-
gesting that an effective efficacy of EI-03 treatment for
EAE development can be achieved at a relative lower
dosage (10 mg/kg). As MS treatment is usually initiated
after the disease has been active and diagnosed, we fur-
ther investigated whether administration of EI-03 was ef-
fective for treating active EAE. We started EI-03
treatment when mice began to show symptoms of EAE.ing the purity of E-recombinant FABP protein (15.3 kDa) used in
rmal stability of E-FABP in the presence of EI-03, as is evident by a Tm
n are representative of three independent experiments.
Figure 3 EI-03 regulates cytokine production by DCs. (A-H) Bone-marrow derived DCs were stimulated with Mtb (50 μg/ml) for 6 hours with the
indicated concentrations of EI-03 or the DMSO control. Cells were lyzed for RNA extraction and cultural supernatants were collected for protein
quantification. Relative mRNA levels of TNFα (A), IL-6 (B), IL-10 (C) and IL-1β (D) were measured by real-time PCR. Protein levels of each cytokine
(E-H) were quantitated by ELISA (*, p < 0.05; **, p < 0.01 as compared to the DMSO control). For measuring expression of co-stimulatory molecules
and MHCII expression, Mtb-stimulated DCs with or without EI-03 were analyzed for CD80 (I), CD86 (J) and MHC II (K) levels with flow cytometry
with respective antibodies. The results shown are representative of three independent experiments.
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ively inhibit EAE symptoms even when administered dur-
ing active disease. Taken together, our results indicate that
EI-03 is effective in suppressing EAE development and
progression, thus representing a promising drug candidate
for treatment of patients with MS.Discussion
MS is an autoimmune disease of the CNS in which
axons are demyelinated due to an attack of activated im-
mune cells. Although many cell types, including oligo-
dendrocytes, epithelial cells and microglial cells, are
involved in the pathogenesis of MS, the crosstalk
Figure 4 (See legend on next page.)
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Figure 4 EI-03 regulates T cell differentiation. Naïve CD4+ T cells were differentiated into Th17 with IL-6 (20 ng/ml) and TGFβ (1 ng/ml) or Th1
with IL-12 (10 ng/ml) for 3 days in the presence or absence of EI-03 (10 μM). Production of IL-17 (A) and IFNγ (B) was measured by intracellular
flow staining. Lymphocytes from LNs were cultured with anti-CD3/CD28 antibody in the presence or absence of EI-03 (10 μM) for 3 days. Foxp3
(C) and IFNγ (D) in CD4+ T cells were examined by intracellular staining. (E) Naïve CD8+ T cells were differentiated with IL-12 (20 ng/ml) in the
presence or absence of EI-03 (10 μM) for 3 days. IFNγ production was examined by intracellular flow staining. Each panel displays a representative
of three experiments yielding similar results. Data are presented as the means ± SD.
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plays a central role in the initiation and progression of
autoimmune responses. While MS is traditionally
thought to be a Th1-cell mediated autoimmune disease,
characterized by IFNγ inflammation, recent work has
demonstrated that other T cell subsets also contribute to
the development of MS. For example, Th17 cells can
produce IL-17 and IL-22 to disrupt blood brain barrier
(BBB) and induce neuronal dysfunction in the CNS
[23,24]; CD8+ T cells have also been shown to be critical
for the pathogenesis of MS [25]. In contrast, these ef-
fector T cell-mediated immune responses are normally
suppressed by Tregs, which are able to maintain im-
mune homeostasis of CNS immunity [26]. Thus, MS is
associated with unbalanced T cell subsets marked by in-
creased frequency of effector T cells and decreased Treg
cells. As MS is a heterogeneous disease involving various
factors and numerous pathogenic cells, treatments tar-
geting a single mediator or one specific cell type may
not be optimal for treatment of MS patients. Herein, we
provide evidence that targeting E-FABP, a lipid carrier
expressed abundantly in immune cells, represents a
novel strategy for modulating the functions of DCs and
T cells for the management of EAE.
In our previous studies, we have demonstrated that E-
FABP expression in CD4+ T cells regulates T cell differ-
entiation and function [10]. In addition, E-FABP is also
highly expressed in DCs, promoting proinflammatory
cytokine production. During the development of EAE,
E-FABP is further upregulated in the CNS, contributing
to EAE pathogenesis through promoting IL-17 and IFNγ
inflammation [11]. Thus, E-FABP overexpression in im-
mune cells may dysregulate their functions to promote
autoreactivity for the development of autoimmune dis-
eases. By taking advantage of the efficient molecular
docking methods [19], we performed a systematic search
of more than 1 million drug-like compounds. Based on
the ranking of the conformational, orientational and
positional space of the docked compounds, we selected
the very best candidates predicted to bind the lipid bind-
ing pocket of E-FABP and experimentally tested their
functions with both in vitro and in vivo models. As E-
FABP regulates T cell differentiation through impacting
nuclear receptor PPARγ expression/activity [10], we first
investigated whether these compounds actively en-
hanced PPARγ expression. Indeed, we showed that EI-03acted like an inhibitor of E-FABP in that it significantly
increased PPARγ expression, mimicking the heightened
PPARγ levels observed in E-FABP deficient T cells. More
importantly, we showed that EI-03 was able to directly
bind to the lipid binding pocket of E-FABP (Figures 1D
and 2), thus functioning as a specific inhibitor of E-
FABP.
To examine the effect of EI-03 on APC functions, we
found that EI-03 potently inhibited proinflammatory
cytokine TNFα production by Mtb-treated DCs. In con-
trast, anti-inflammatory cytokine IL-10 was upregulated
by EI-03 treatment. This phenotype is consistent with
what we have seen in E-FABP deficient DCs. Since DCs
also express A-FABP, although to a much less extent, we
cannot exclude the possibility that EI-03 may bind to A-
FABP contributing to the observed phenotype. As EI-03
treatment may impair the production of Th-differentiation
related cytokines, such as IL-6, by DCs, we further ana-
lyzed the effect of EI-03 on T cell differentiation. We con-
firmed that EI-03 decreases IL-17 production while
increasing Foxp3 expression in T cells, which corresponds
to the effects observed in E-FABP deficient T cells. Not-
ably, E-FABP is the predominant FABP member in T cells
(unpublished data), it is reasonable to speculate that EI-03
may also regulate T cell differentiation through direct tar-
geting E-FABP in T cells. In addition, EI-03 was also
showed to inhibit IFNγ production both in CD4+ T cells
and in CD8+ T cells, implying that EI-03 may exhibit a
more broad effect in controlling the function of DCs and
the differentiation of T cell subsets for treatment of T cell-
mediated autoimmune diseases.
As studies of EAE have contributed to several ap-
proved MS medications [27], we used this model to fur-
ther investigate the therapeutic efficacy of EI-03 in vivo.
EI-03 administration significantly suppresses the clinical
symptoms during EAE development (Figures 5 and 6).
Further analysis showed that EI-03 treatment inhibited
T cell migration into the CNS as well as the production
of IL-17 and IFNγ of the infiltrated populations. Notably,
when we titrated the dosage of EI-03 in mouse models,
we did not observe any apparent toxicity of EI-03 even
at the dose of 20 mg/kg/day, regarding overall health
condition, total cell counts and apoptotic status of per-
ipheral blood, and activation markers of immune cells
(data not shown). Thus, EI-03 is well tolerated when ap-
plied in vivo. Since PPARγ agonists have been shown to
Figure 5 Amelioration of EAE is associated with reduced leucocyte infiltration and effector T cell function in EI-03-treated mice. (A) C57B/6 mice
treated with EI-03 or DMSO vehicle control (n = 9/group) were immunized with MOG35–55 and scored daily postimmunization (*, p < 0.05).
(B) EAE mice from EI-03-treated or control mice were sacrificed at the peak of the disease and total numbers of mononuclear cells in the CNS of
those mice were measured with an automatic cell-counter. Percentage of infiltrated CD4+ T cells (C), CD8+ T cells (D) and CD11b+MHCII+ cells
(E) were analyzed by flow cytometric staining. The expression of IL-17, IFNγ (F) and Foxp3 (G) in CNS-infiltrated CD4+ T cells were determined
using intracellular staining. (H) Total numbers of IFNγ+ CD8+ T cells in CNS were measured using intracellular staining. The results shown are
representative of three independent experiments (*, p < 0.05).
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Figure 6 EI-03 treatment inhibits EAE disease. (A) Different dosages of
EI-03 were administered to mice at the beginning of EAE induction with
MOG immunization (n = 9/group). Vehicle DMSO was administered as
non-treated controls. Clinical scores were measured daily (*, p < 0.05).
(B) EI-03 compounds (10 mg/kg) were administered to mice on day 8
after EAE induction with MOG (n = 9/group). Average clinical scores were
shown in panel B (*, p < 0.05).
Rao et al. BMC Immunology  (2015) 16:28 Page 11 of 12reduce clinical signs of EAE [28], we cannot exclude the
possibility that administration of EI-03 in vivo may dir-
ectly activate other targets, including PPARγ to exert its
protective effects on EAE development. In addition, it
warrants further investigation as to whether EI-03 treat-
ment affects functions of other populations besides DCs
and T cells during EAE development.
Conclusion
In summary, we have demonstrated that targeting E-
FABP represents a novel strategy for treatment of EAE.
Using a molecular docking model, we identified a new
E-FABP inhibitor which can regulate functions of both
APCs and T cells. Further analyses with animal models
of MS revealed a therapeutic benefit of the inhibitor in
ameliorating clinical symptoms of EAE through inhib-
ition of lymphocyte migration and pathogenic functions.Thus, these data suggest that this newly-identified in-
hibitor may be a new drug candidate for treatment of
MS and other autoimmune diseases.
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